The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Open accessAbstract
SUMMARY Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown
Pertea, M., Kim, D., Pertea, G. M., Leek, J. T., & Salzberg, S. L. (2016) · Nature Protocols · doi:10.1038/nprot.2016.095 · Cited by 6,845
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationMi, H., Muruganujan, A., Ebert, D., Huang, X., & Thomas, P. D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1038 · Cited by 3,033
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Sambamba: fast processing of NGS alignment formats
Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J., & Prins, P. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv098 · Cited by 2,413
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Self-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Self-citationErez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationSu, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Self-citationKu, S. Y., Rosario, S., Wang, Y., Mu, P., Seshadri, M., Goodrich, Z. W., Goodrich, M. M., Labbé, D. P., Gomez, E. C., Wang, J., et al. (2017) · Science · doi:10.1126/science.aah4199 · Cited by 1,089
Self-citationStromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S.-Y., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,050
Self-citationNeuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Self-citationSun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Straussman et al., 2012; Su et al., 2018; Sun et al., 2012).”
BackgroundMicroenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Karthaus, W. R., Iaquinta, P. J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C. M., Gao, D., Begthel, H., Sachs, N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.017 · Cited by 727
Self-citationAn Optimized microRNA Backbone for Effective Single-Copy RNAi
Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M., Lai, D. Y., Barbosa, I. A. M., Kwon, J. S., Guan, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.020 · Cited by 719
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010) · Nature · doi:10.1038/nature08782 · Cited by 639
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.005 · Cited by 624
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
fastcluster: Fast Hierarchical, Agglomerative Clustering Routines for R and Python
Müllner, D. (2013) · Journal of Statistical Software · doi:10.18637/jss.v053.i09 · Cited by 605
Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases
Mei, L., & Nave, K.-A. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.007 · Cited by 592
Pten in stromal fibroblasts suppresses mammary epithelial tumours
Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J.-L., et al. (2009) · Nature · doi:10.1038/nature08486 · Cited by 500
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428
Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma
Zhang, X. H.-F., Jin, X., Malladi, S., Zou, Y., Wen, Y. H., Brogi, E., Smid, M., Foekens, J. A., & Massagué, J. (2013) · Cell · doi:10.1016/j.cell.2013.07.036 · Cited by 425
Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399
Self-citationOvercoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Self-citationIl-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Viswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365 · cited 1×
“, 2015), as well as tandem duplication events involving the AR enhancer (Quigley et al., 2018; Takeda et al., 2018; Viswanathan et al., 2018).”
BackgroundSelf-citationThe role of fibroblast growth factors and their receptors in prostate cancer
Kwabi-Addo, B., Ozen, M., & Ittmann, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00535 · Cited by 350
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 16×
“22Pc-CAFCM also promoted resistance to CSS and Enz in two additional androgen-dependent human prostate models, the VCaP cell line and the patient-derived cancer organoid MSK-PCa2 (Figures S2C–S2F).”
MethodInfluentialHepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
Humphrey, P. A., Zhu, X., Zarnegar, R., Swanson, P. E., Ratliff, T. L., Vollmer, R. T., & Day, M. L. (1995) · Europe PMC (PubMed Central) · Cited by 335
Cunha, G. R. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3+<1030::aid-cncr2820741510>3.0.co;2-q · Cited by 328
Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317
Establishing Primary Adult Fibroblast Cultures From Rodents
Seluanov, A., Vaidya, A., & Gorbunova, V. (2010) · Journal of Visualized Experiments · doi:10.3791/2033 · Cited by 289
Taplin, M.-E., Montgomery, B., Logothetis, C. J., Bubley, G. J., Richie, J. P., Dalkin, B. L., Sanda, M. G., Davis, J. W., Loda, M., True, L. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.4578 · Cited by 284
Self-citationRegenerative potential of prostate luminal cells revealed by single-cell analysis
Karthaus, W. R., Hofree, M., Choi, D., Linton, E. L., Turkekul, M., Bejnood, A., Carver, B., Gopalan, A., Abida, W., Laudone, V., et al. (2020) · Science · doi:10.1126/science.aay0267 · Cited by 283
Self-citationChen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B. S., Wongvipat, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3216 · Cited by 282
Self-citationSmith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Heining, C., Horak, P., Uhrig, S., Codo, P. L., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R. K., Greulich, H., Schinzel, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.047 · Cited by 234
Cunha, G. R., & Chung, L. W. K. (1981) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(81)90338-1 · Cited by 229
Detection of NRG1 Gene Fusions in Solid Tumors
Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., Ma, P. C., Nieva, J. J., Spira, A. I., Vanderwalde, A. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0160 · Cited by 227
Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., Smith, R. S., Delasos, L., Vojnic, M., Plodkowski, A. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1004 · Cited by 202
Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W., Armenia, J., Rockowitz, S., Drier, Y., Bernstein, B. E., Long, H. W., et al. (2017) · eLife · doi:10.7554/elife.27861 · Cited by 201
Self-citationAltered TGF-β Signaling in a Subpopulation of Human Stromal Cells Promotes Prostatic Carcinogenesis
Franco, O. E., Jiang, M., Strand, D. W., Peacock, J., Fernandez, S., Jackson, R. S., Revelo, M. P., Bhowmick, N. A., & Hayward, S. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3142 · Cited by 182
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D. (2004) · The Prostate · doi:10.1002/pros.20065 · Cited by 181
Nagashima, T., Shimodaira, H., Ide, K., Nakakuki, T., Tani, Y., Takahashi, K., Yumoto, N., & Hatakeyama, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608653200 · Cited by 177
Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer
Dakhova, O., Ozen, M., Creighton, C. J., Li, R., Ayala, G., Rowley, D., & Ittmann, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1899 · Cited by 166
Zhang, Z., Zhou, C., Li, X., Barnes, S. D., Deng, S., Hoover, E., Chen, C.-C., Lee, Y. S., Zhang, Y., Wang, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.001 · Cited by 166
Self-citationJones, M. R., Williamson, L., Topham, J. T., Lee, M. K. C., Goytain, A., Ho, J., Denroche, R. E., Jang, G.-H., Pleasance, E., Shen, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0191 · Cited by 162
Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., & Settleman, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.011 · Cited by 161
Dhanasekaran, S. M., Balbin, O. A., Chen, G., Nadal, E., Sundaram, S. K., Pan, J., Veeneman, B. A., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 160
Bono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 141
Neoadjuvant Enzalutamide Prior to Prostatectomy
Montgomery, B., Tretiakova, M., Joshua, A. M., Gleave, M. E., Fleshner, N. E., Bubley, G. J., Mostaghel, E. A., Chi, K. N., Lin, D. W., Sanda, M. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1357 · Cited by 140
Self-citationHER‐2 profiling and targeting in prostate carcinoma
Morris, M. J., Reuter, V. E., Kelly, W. K., Slovin, S. F., Kenneson, K., Verbel, D., Osman, I., & Scher, H. I. (2002) · Cancer · doi:10.1002/cncr.10339 · Cited by 138
Tyekucheva, S., Bowden, M., Bango, C., Giunchi, F., Huang, Y., Zhou, C. W., Bondi, A., Lis, R. T., Hemelrijck, M. V., Andrén, O., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00460-4 · Cited by 124
Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M. D., Goel, S., Qi, X., Shankaraiah, R. C., Cao, Z. A., Ramjiawan, R. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4682 · Cited by 115
Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma
Lara, P. N., Chee, K. G., Longmate, J., Ruel, C., Meyers, F. J., Gray, C. R., Edwards, R. G., Gumerlock, P. H., Twardowski, P. W., Doroshow, J. H., et al. (2004) · Cancer · doi:10.1002/cncr.20228 · Cited by 114
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 111
LoRusso, P. M., Janne, P. A., de Oliveira, M. R., Rizvi, N. A., Malburg, L., Keedy, V. L., Yee, L., Copigneaux, C., Hettmann, T., Wu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3051 · Cited by 93
Self-citationWhang, Y. E., Armstrong, A. J., Rathmell, W. K., Godley, P. A., Kim, W. Y., Pruthi, R. S., Wallen, E., Crane, J. M., Moore, D. T., Grigson, G., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.018 · Cited by 89
Hegde, G. V., de la Cruz, C. C., Chiu, C., Alag, N., Schaefer, G., Crocker, L., Ross, S., Goldenberg, D., Merchant, M. A., Tien, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004438 · Cited by 89
Role for Stromal Heterogeneity in Prostate Tumorigenesis
Kiskowski, M. A., Jackson, R. S., Banerjee, J., Li, X., Kang, M., Iturregui, J. M., Franco, O. E., Hayward, S. W., & Bhowmick, N. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2999 · Cited by 88
Sharon, Y., Alon, L. T., Glanz, S., Servais, C., & Erez, N. (2013) · Journal of Visualized Experiments · doi:10.3791/4425 · Cited by 87
Zhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K. A., Asara, J. M., Costa, D. B., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0052-9 · Cited by 84
Sridhar, S. S., Hotte, S. J., Chin, J. L., Hudes, G. R., Gregg, R. W., Trachtenberg, J., Wang, L. E., Tran‐Thanh, D., Pham, N., Tsao, M., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181beac33 · Cited by 78
Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation
Clocchiatti, A., Ghosh, S., Procopio, M.-G., Mazzeo, L., Bordignon, P., Ostano, P., Goruppi, S., Bottoni, G., Katarkar, A., Levesque, M. P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99159 · Cited by 70
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer
Gao, S., Ye, H., Gerrin, S. J., Wang, H., Sharma, A. M., Chen, S., Patnaik, A., Sowalsky, A. G., Voznesensky, O. S., Han, W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2309 · Cited by 52
Self-citationDagvadorj, A., Tan, S., Liao, Z., Cavalli, L. R., Haddad, B. R., & Nevalainen, M. T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0979 · Cited by 45
Sharon, Y., Alon, L. T., Glanz, S., Servais, C., & Erez, N. (2013) · Journal of Visualized Experiments · doi:10.3791/4425-v · Cited by 40
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1001 · Cited by 28
Hwang, C., Choi, J., Zhou, Z., Flesken‐Nikitin, A., Tarakhovsky, A., & Nikitin, A. Y. (2011) · Cell Cycle · doi:10.4161/cc.10.22.18294 · Cited by 24
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma
Hegde, G. V., de la Cruz, C., Giltnane, J. M., Crocker, L., Venkatanarayan, A., Schaefer, G., Dunlap, D. Y., Hoeck, J. D., Piskol, R., Gnad, F., et al. (2019) · eLife · doi:10.7554/elife.46551 · Cited by 14
Cited by
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
Liang, D., Feng, Y., Zandkarimi, F., Wang, H., Zhang, Z., Kim, J., Cai, Y., Gu, W., Stockwell, B. R., & Jiang, X. (2023) · Cell · doi:10.1016/j.cell.2023.05.003 · Cited by 722
Self-citationZhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R. P., Calì, B., Attanasio, G., Troisi, J., Minini, M., Mosole, S., et al. (2021) · Science · doi:10.1126/science.abf8403 · Cited by 323
Metadata
- Authors
- Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W., Linton, E., Lee, E., Barnes, S. D., Chen, H.-A., Mao, N., Wongvipat, J., Choi, D., Chen, X., Zhao, H., Manova-Todorova, K., de Stanchina, E., Taplin, M.-E., Balk, S. P., Rathkopf, D. E., Gopalan, A., Carver, B. S., Mu, P., Jiang, X., Watson, P. A., & Sawyers, C. L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 38
- Issue
- 2
- Pages
- 279-296.e9
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3043502623
- Cited by
- 259
- References
- 89
- FWCI
- 16.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.